JP2019513370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513370A5 JP2019513370A5 JP2018551953A JP2018551953A JP2019513370A5 JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5 JP 2018551953 A JP2018551953 A JP 2018551953A JP 2018551953 A JP2018551953 A JP 2018551953A JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- amino acid
- acid sequence
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317068P | 2016-04-01 | 2016-04-01 | |
| US62/317,068 | 2016-04-01 | ||
| PCT/US2017/025573 WO2017173384A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152515A Division JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513370A JP2019513370A (ja) | 2019-05-30 |
| JP2019513370A5 true JP2019513370A5 (enExample) | 2019-10-24 |
Family
ID=59960746
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551953A Pending JP2019513370A (ja) | 2016-04-01 | 2017-03-31 | キメラ受容体及びその使用方法 |
| JP2020152515A Active JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
| JP2022136417A Active JP7451627B2 (ja) | 2016-04-01 | 2022-08-30 | キメラ受容体及びその使用方法 |
| JP2024033511A Active JP7673272B2 (ja) | 2016-04-01 | 2024-03-06 | キメラ受容体及びその使用方法 |
| JP2025071243A Pending JP2025111619A (ja) | 2016-04-01 | 2025-04-23 | キメラ受容体及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152515A Active JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
| JP2022136417A Active JP7451627B2 (ja) | 2016-04-01 | 2022-08-30 | キメラ受容体及びその使用方法 |
| JP2024033511A Active JP7673272B2 (ja) | 2016-04-01 | 2024-03-06 | キメラ受容体及びその使用方法 |
| JP2025071243A Pending JP2025111619A (ja) | 2016-04-01 | 2025-04-23 | キメラ受容体及びその使用方法 |
Country Status (33)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| SG11201808138YA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole derivatives as dengue viral replication inhibitors |
| MA44498A (fr) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |
| KR102608405B1 (ko) | 2016-04-01 | 2023-12-01 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| US10603380B2 (en) | 2016-04-01 | 2020-03-31 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3436004B1 (en) | 2016-04-01 | 2024-12-11 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| SI3630724T1 (sl) | 2017-05-22 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituirani derivati indolina kot zaviralci replikacije virusa denga |
| WO2019099707A1 (en) * | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
| CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| US20210292389A1 (en) * | 2018-08-10 | 2021-09-23 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
| WO2020083406A1 (zh) * | 2018-10-26 | 2020-04-30 | 科济生物医药（上海）有限公司 | 靶向cll1的抗体及其应用 |
| US11673953B2 (en) | 2019-03-01 | 2023-06-13 | Allogene Therapeutics, Inc. | DLL3 targeting chimeric antigen receptors and binding agents |
| EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えａｄ３５ベクター及び関連遺伝子治療改善 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| EP4028031A4 (en) * | 2019-09-13 | 2023-09-06 | Memorial Sloan Kettering Cancer Center | ANTIGEN RECOGNITION RECEPTORS TARGETING CD371 AND THEIR USES |
| CN113234169B (zh) | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113896795B (zh) | 2020-12-11 | 2022-07-15 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113416713A (zh) * | 2021-05-11 | 2021-09-21 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种重组腺病毒的构建及其应用 |
| CN115521917A (zh) * | 2021-06-25 | 2022-12-27 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| EP4469478A1 (en) | 2022-01-26 | 2024-12-04 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targetted antigen |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| WO2024186695A2 (en) * | 2023-03-03 | 2024-09-12 | Trustees Of Boston University | Immune cell fusion (icf) and uses thereof |
| JP2026512487A (ja) * | 2023-04-18 | 2026-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａキメラ抗原受容体及びその使用 |
| WO2025194098A1 (en) | 2024-03-14 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same |
| TW202604957A (zh) * | 2024-05-03 | 2026-02-01 | 美商凱特製藥公司 | 嵌合受體及其使用方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| WO2005000894A2 (en) | 2003-06-25 | 2005-01-06 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DE112005002126B4 (de) | 2004-09-03 | 2018-05-09 | General Motors Corp. | Ausrichtungssystem und -verfahren für sich wiederholende und nicht wiederholende Einheiten in einem Brennstoffzellenstapel |
| WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| AU2010320547B2 (en) | 2009-11-17 | 2016-06-09 | Basf Plant Science Company Gmbh | Plants with increased yield |
| US20130052663A1 (en) | 2010-05-05 | 2013-02-28 | Addex Pharma Sa | Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2614077B1 (en) | 2010-09-08 | 2016-08-17 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| SI3415531T1 (sl) | 2011-05-27 | 2023-12-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - vezni proteini |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| AU2014214850C1 (en) | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| SI3300745T1 (sl) | 2013-02-15 | 2020-01-31 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njihove uporabe |
| EP2968502B1 (en) | 2013-03-14 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| AU2014352638B2 (en) | 2013-11-25 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| CN106459915A (zh) | 2014-02-04 | 2017-02-22 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| JP6736540B2 (ja) * | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
| EP3587446A1 (en) | 2014-09-19 | 2020-01-01 | City of Hope | Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2 |
| CA2969704C (en) | 2014-12-05 | 2023-05-02 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| IL310723A (en) | 2015-04-13 | 2024-04-01 | Pfizer | Therapeutic antibodies and their uses |
| KR102694879B1 (ko) | 2016-04-01 | 2024-08-16 | 암젠 인크 | Flt3에 대한 키메라 수용체 및 이의 사용 방법 |
| KR102608405B1 (ko) | 2016-04-01 | 2023-12-01 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| US10603380B2 (en) | 2016-04-01 | 2020-03-31 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
-
2017
- 2017-03-31 KR KR1020227039755A patent/KR102608405B1/ko active Active
- 2017-03-31 KR KR1020207015941A patent/KR20200068750A/ko not_active Ceased
- 2017-03-31 AU AU2017240788A patent/AU2017240788B2/en active Active
- 2017-03-31 SI SI201731265T patent/SI3436030T1/sl unknown
- 2017-03-31 ES ES17776859T patent/ES2930058T3/es active Active
- 2017-03-31 AR ARP170100821A patent/AR108066A1/es unknown
- 2017-03-31 MY MYPI2018703599A patent/MY197669A/en unknown
- 2017-03-31 BR BR112018070260A patent/BR112018070260A2/pt active Search and Examination
- 2017-03-31 PL PL17776859.5T patent/PL3436030T3/pl unknown
- 2017-03-31 CR CR20210084A patent/CR20210084A/es unknown
- 2017-03-31 PE PE2018001934A patent/PE20190356A1/es unknown
- 2017-03-31 HR HRP20221348TT patent/HRP20221348T1/hr unknown
- 2017-03-31 LT LTEPPCT/US2017/025573T patent/LT3436030T/lt unknown
- 2017-03-31 KR KR1020237040899A patent/KR102731644B1/ko active Active
- 2017-03-31 KR KR1020217021089A patent/KR20210089262A/ko not_active Ceased
- 2017-03-31 SM SM20220444T patent/SMT202200444T1/it unknown
- 2017-03-31 WO PCT/US2017/025573 patent/WO2017173384A1/en not_active Ceased
- 2017-03-31 PE PE2019002307A patent/PE20200400A1/es unknown
- 2017-03-31 CN CN202511224360.4A patent/CN121108368A/zh active Pending
- 2017-03-31 SG SG10201912519VA patent/SG10201912519VA/en unknown
- 2017-03-31 PE PE2020001605A patent/PE20211418A1/es unknown
- 2017-03-31 MX MX2018012019A patent/MX2018012019A/es unknown
- 2017-03-31 KR KR1020187031572A patent/KR102120815B1/ko active Active
- 2017-03-31 CN CN201780022074.7A patent/CN109641008B/zh active Active
- 2017-03-31 EA EA201891992A patent/EA201891992A1/ru unknown
- 2017-03-31 CA CA3177398A patent/CA3177398A1/en active Pending
- 2017-03-31 PT PT177768595T patent/PT3436030T/pt unknown
- 2017-03-31 US US15/476,699 patent/US10597456B2/en active Active
- 2017-03-31 IL IL316403A patent/IL316403A/en unknown
- 2017-03-31 EP EP22191077.1A patent/EP4180449A1/en active Pending
- 2017-03-31 UA UAA201809953A patent/UA123276C2/uk unknown
- 2017-03-31 CN CN202110248927.7A patent/CN113150170B/zh active Active
- 2017-03-31 DK DK17776859.5T patent/DK3436030T3/da active
- 2017-03-31 UA UAA201909739A patent/UA128781C2/uk unknown
- 2017-03-31 HU HUE17776859A patent/HUE060645T2/hu unknown
- 2017-03-31 CA CA3019650A patent/CA3019650C/en active Active
- 2017-03-31 SG SG11201808595WA patent/SG11201808595WA/en unknown
- 2017-03-31 KR KR1020257007542A patent/KR20250039495A/ko active Pending
- 2017-03-31 KR KR1020247037911A patent/KR102779944B1/ko active Active
- 2017-03-31 CR CR20180480A patent/CR20180480A/es unknown
- 2017-03-31 IL IL262041A patent/IL262041B2/en unknown
- 2017-03-31 RS RS20221024A patent/RS63735B1/sr unknown
- 2017-03-31 EP EP17776859.5A patent/EP3436030B1/en active Active
- 2017-03-31 MA MA43603A patent/MA43603A1/fr unknown
- 2017-03-31 JP JP2018551953A patent/JP2019513370A/ja active Pending
- 2017-04-05 TW TW113133719A patent/TWI909673B/zh active
- 2017-04-05 TW TW106111224A patent/TW201803896A/zh unknown
- 2017-04-05 TW TW109145084A patent/TWI792123B/zh active
- 2017-04-05 TW TW112101087A patent/TWI855499B/zh active
- 2017-04-05 TW TW109107507A patent/TWI714470B/zh active
-
2018
- 2018-10-01 PH PH12018502113A patent/PH12018502113A1/en unknown
- 2018-10-01 CL CL2018002797A patent/CL2018002797A1/es unknown
- 2018-10-01 MX MX2023002556A patent/MX2023002556A/es unknown
- 2018-10-01 CO CONC2018/0010547A patent/CO2018010547A2/es unknown
-
2019
- 2019-08-14 CL CL2019002310A patent/CL2019002310A1/es unknown
- 2019-10-21 US US16/658,480 patent/US20200115457A1/en not_active Abandoned
-
2020
- 2020-06-15 AU AU2020203990A patent/AU2020203990A1/en not_active Abandoned
- 2020-09-11 JP JP2020152515A patent/JP7134204B2/ja active Active
- 2020-10-15 CL CL2020002677A patent/CL2020002677A1/es unknown
-
2021
- 2021-06-30 CL CL2021001750A patent/CL2021001750A1/es unknown
-
2022
- 2022-07-08 CL CL2022001873A patent/CL2022001873A1/es unknown
- 2022-08-30 JP JP2022136417A patent/JP7451627B2/ja active Active
-
2023
- 2023-03-03 US US18/178,086 patent/US20230331855A1/en active Pending
- 2023-07-24 AU AU2023208077A patent/AU2023208077A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033511A patent/JP7673272B2/ja active Active
-
2025
- 2025-04-23 JP JP2025071243A patent/JP2025111619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019243665B2 (en) | Multivalent antibody | |
| CN111018986B (zh) | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 | |
| CA3116294C (en) | Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same | |
| WO2018108106A1 (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| JP2020508655A5 (enExample) | ||
| JP2022504802A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| US10927176B2 (en) | Tumor-specific anti-EGFR antibody and application thereof | |
| JP2022514693A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2016536322A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2022542559A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| KR20230143177A (ko) | 신규한 항-cd24 항체 | |
| JP2024001073A5 (enExample) | ||
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2022529380A5 (enExample) | ||
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| AU2020400801B2 (en) | Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof | |
| JP2024541476A5 (enExample) | ||
| JP2024546923A5 (enExample) | ||
| JP2021529539A5 (enExample) | ||
| KR20210046725A (ko) | 신규 암 면역요법 항체 조성물 |